Agilent Gains Design Support from CRB for Manufacturing Facility Expansion
Agilent’s therapeutic nucleic acids facility gains architectural design support from CRB.
CRB announced on Feb. 17, 2023 that it will be providing design support for Agilent’s manufacturing facility expansion in Frederick, Colo. The expansion will double Agilent’s manufacturing capacity of nucleic acid therapeutics.
Agilent’s two new manufacturing lines will help the company meet rapid growth within the nucleic acids market and strong demand for its APIs. CRB is working under Flour Corporation to deliver process design, process utilities, current good manufacturing practices architecture, and equipment procurement support for the facility’s new therapeutic nucleic acid manufacturing lines.
“Agilent’s facility will be a powerful tool in the effort to deliver these critical, life-saving therapies to patients,” said Jake Adams, senior project manager and RNA therapies market sector lead for CRB, in a company press release. “We are thrilled to help deliver Agilent’s difference-making solution.”
Source: CRB
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
